News

At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.

At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.

The investigators conducted a retrospective chart review of patients’ demographic and clinical data from 2005 to 2020.

Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.

Philip P. Storey, MD, shares the highlights of his ARVO presentation on a post hoc analysis of the pivotal TENAYA/LUCERNE trials.

With the progression of MS, thinning of the retinal ganglion cell (RGC) complex is seen as well as a decrease in the amplitude of the pattern electroretinogram (pERG)

The almost 474,000 participants in the study had been diagnosed with uveitis between January 1, 2015, and February 25, 2021 in South Korea.

Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.

The data will be presented in oral session at the 2024 American Society of Gene & Cell Therapy meeting May 7-11 in Baltimore, Maryland.

Joseph Izatt was a skilled researcher and inventor who played a foundational role in the development of optical coherence tomography.

Several presentations will provide research updates on various topics related to retinal vein occlusion (RVO).

As the annual ARVO conference draws closer, more companies have released information on presentations related to their pipeline and new data.

The intent of this extension is to assess potentially greater durability compared to aflibercept and will increase the statistical power of the study.

This initiative will provide a variety of tools to promote awareness and education, including some resources in both English and Spanish.

The collaboration will bring automated, AI-powered OCT segmentation to MICRON Software Suite.

Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations the ARVO annual conference, being held in Seattle, Washington. More companies are expected to announce their presentations in the coming days.

The Vision Simulator shows disease progression and vision loss simulations for diabetic macular edema, diabetic retinopathy, AMD, XLRP, and achromatopsia.

The WVU Health System Board of Directors recently approved $233.5 million to fund the construction of a multi-center outpatient facility with additional exam and testing rooms.

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

According to the company, OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene.

According to the company, 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

According to the company, SGT-1001 uses its novel gene coding technology for gene integration via transposition. It plans to advance SGT-1001 into the clinic in the first half of 2025. Preclinical data for SGT-1001 will be presented at the Association for Research in Vision and Ophthalmology and the American Society of Gene & Cell Therapy annual meetings.

Rising costs of metabolic agents, particularly those used in the treatment of diabetes, impacts patients and the medical systems, such as Medicare and Medicaid.

Through free, virtual webinars, the companies are working to bring clinical education to eye care professionals around the world.

The program will use OCT images to identify and monitor AMD in its early stages.